A Case of PMR ‐Like irAE Developing After Treatment With Ipilimumab and Nivolumab for Lung Cancer
Ryuichi Utsumi, Hideki Terai, Tetsuya Arai, Yu Iwabuchi, Mitsuhiro Akiyama, Shigenari Nukaga, Keiko Ohgino, Hiroki Kabata, Shotaro Chubachi, Hiroyuki Yasuda, Koichi Fukunaga ABSTRACT
Immune‐checkpoint inhibitors (ICIs) have become one of the main strategies for advanced cancers. ICIs are associated with many immune side effects, called immune‐related adverse events (irAEs). Since irAE has various variations, it is important to carefully examine each individual case that develops irAE. We experienced a case of polymyalgia rheumatica (PMR)‐like irAE after three courses of administration of Ipilimumab and Nivolumab for stage IV lung adenocarcinoma. We also confirmed that the activity of this irAE was detectable on the PET‐CT scan performed to assess lung cancer progression. Given the limited reports of PMR‐like irAE occurring after treatment with two immune checkpoint inhibitors, we present this case along with a review of the literature.